Shamburg News · 8-K/A filed Nov 16, 2026, 4:15 PM EST

Cumberland Pharmaceuticals Reports Top-Line Results From ASSIST-SSc Phase 2a Trial of Ifetroban

CPIX · CUMBERLAND PHARMACEUTICALS INC

  • Other event
  • Materiality: medium

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in systemic sclerosis, reporting the drug was generally well tolerated. The trial enrolled 31 subjects receiving ifetroban and 10 receiving placebo, with a modest increase in bleeding-related and gastrointestinal adverse events in the ifetroban group. The company stated the trial was not designed or powered to evaluate efficacy, and plans to submit the clinical study report to the FDA and complete correlative biomarker and cardiac imaging evaluations.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K/A, Item 9.01, accession 0001087294-26-000086.

Written from the filing by Shamburg Markets. Figures are as reported by the company.